Is Agios Pharmaceuticals, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Agios Pharmaceuticals, Inc. has moved from very attractive to attractive. The company appears to be undervalued based on its current metrics, particularly with a P/E ratio of 4, a PEG ratio of 0.01, and an EV to EBITDA of -3.81. In comparison to peers, PTC Therapeutics, Inc. has a P/E of 5.85, while Supernus Pharmaceuticals, Inc. is considered expensive with a P/E of 37.12.
Despite the recent downgrade in valuation grade, Agios Pharmaceuticals has shown strong short-term performance, with a year-to-date return of 28.82% compared to the S&P 500's 13.30%. However, over the longer term, the stock has underperformed the index, with a 1-year return of -4.10% versus the S&P 500's 14.08%. Overall, the current valuation metrics suggest that Agios Pharmaceuticals is positioned as an attractive investment opportunity.